Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis.

Autor: Zuhair V; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Obaid MA; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Mustafa MS; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Shafique MA; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Rangwala BS; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Shakil A; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Babar A; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Rangwala HS; Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan., Obaid MI; Department of Medicine, Bahria University of Health Sciences, Karachi, Pakistan.
Jazyk: angličtina
Zdroj: Journal of diabetes and metabolic disorders [J Diabetes Metab Disord] 2024 Apr 23; Vol. 23 (1), pp. 1337-1349. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024).
DOI: 10.1007/s40200-024-01431-5
Abstrakt: Introduction: Various insulin therapies for Diabetes Mellitus offer different benefits while having potential risks. We aim to compare Insulin Icodec, a novel Insulin analogue with the ease of once-weekly administration, to the once-daily Insulin Glargine U100 regarding glycemic control and safety profile.
Methods: We performed a systematic literature search of electronic databases for peer-reviewed articles from inception until September 1 2023.
Results: A total of 2215 type 2 diabetic patients were included, of which 1209 received Insulin Icodec and1048 recieved Insulin Glargine U100. In terms of glycemic control, Insulin Icodec showed a significantly longer time in the target glucose range (MD: 0.304, CI: 0.069, P  = 0.000) and a more significant reduction in HbA1c (MD: -0.154, CI: 0.003, P  = 0.005) compared to Insulin Glargine U100. Fasting Plasma Glucose did not differ significantly. Insulin Icodec led to a more significant increase in body weight (MD: 0.161 kg, P  = 0.029), while Insulin Glargine required a higher insulin dose (MD: 1.920 IU, P  = 0.000). Regarding safety, the two groups had no significant differences in hypoglycemic events or adverse outcomes.
Conclusion: Once-weekly Insulin Icodec demonstrates superior glycemic control with a reduced HbA1c compared to Once-Daily Insulin Glargine U100 while maintaining similar safety profiles.
Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-024-01431-5.
Competing Interests: Competing interestsThe authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
(© The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: